What Should a Psychiatrist Know About Genetics?:
Review and Recommendations From the Residency Education Committee of the
International Society of Psychiatric Genetics

John I. Nurnberger Jr, MD,PhD a,*, Jehannine Austin, PhD b, Wade H. Berrettini, MD,PhD c, Aaron D. Besterman, MD d, Lynn E. DeLisi, MD e, Dorothy E. Grice, MD f, James L. Kennedy, MD g, Daniel Moreno-De-Luca, MD h, James B. Potash, MD,MPH i, David A. Ross, MD,PhD i, Thomas G. Schulze, MD k, and Gwyneth Zai, MD,PhD k

aIndiana University School of Medicine, Indianapolis, Indiana
bUniversity of British Columbia, Vancouver, British Columbia, Canada
cUniversity of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
dUniversity of California Los Angeles Semel Institute of Neuroscience and Human Behavior, Los Angeles, California
VA Boston Healthcare System and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts
eMt Sinai School of Medicine, New York, New York
fCentre for Addiction and Mental Health and University of Toronto, Toronto, Ontario, Canada
gCentre for Addiction and Mental Health and University of Toronto, Toronto, Ontario, Canada
hWarren Alpert Medical School of Brown University, Providence, Rhode Island
iJohns Hopkins University School of Medicine, Baltimore, Maryland
jY ale University School of Medicine, Hartford, Connecticut
kInstitute of Psychiatric Phenomics and Genomics, University Hospital, LMU Munich, Munich, Germany

Abstract

The International Society of Psychiatric Genetics (ISPG) created a Residency Education Committee with the purpose of identifying key genetic knowledge that should be taught in psychiatric training programs. Thirteen committee members were appointed by the ISPG Board of Directors, based on varied training, expertise, gender, and national origin. The Committee has met quarterly for the past 2 years, with periodic reports to the Board and to the members of the Society. The information summarized includes the existing literature in the field of psychiatric genetics and the output of ongoing large genomics consortia. An outline of clinically relevant areas of genetic knowledge was developed, circulated, and approved. This document was expanded and annotated with appropriate references, and the manuscript was developed. Specific information regarding the contribution of common and rare genetic variants to major psychiatric disorders and treatment response is now available. Current challenges include the following: (1) Genetic testing is recommended in the evaluation of autism and intellectual disability, but its use is limited in current clinical practice. (2) Commercial pharmacogenomic testing is widely available, but its utility has

*Corresponding author: John I. Nurnberger Jr, MD, PhD, 320 W 15th St, Indianapolis, IN 46202 (jnurnber@iupui.edu).

Previous presentation: World Congress of Psychiatric Genetics, October 30-November 4, 2016, Jerusalem, Israel, and October 13–17, 2017, Orlando, Florida; and Psychiatric Research Society, February 2016, Park City, Utah.

Supplementary material: Available at PSYCHIATRIST.COM.

Potential conflicts of interest: Dr Nurnberger is an investigator for Assurex and for Janssen. Dr Kennedy is on the scientific advisory board for Assurex (unpaid) and has received honoraria from Shire and Novartis for lectures. The other authors report no potential conflict of interest.
not yet been clearly established. (3) Other methods, such as whole exome and whole genome sequencing, will soon be clinically applicable. The need for informed genetic counseling in psychiatry is greater than ever before, knowledge in the field is rapidly growing, and genetic education should become an integral part of psychiatric training.

Many of the major psychiatric disorders have a high heritability, reflecting a strong genetic component. The genetic architecture of these disorders is becoming clearer (Table 1).

Psychiatrists are already confronted with questions about genetics in their daily work. Patients want to know the risks of passing on illness to offspring. They may ask about genetic testing for pharmacologic treatment selection. Sometimes they will bring such information to their clinicians from the internet or from DNA test results.

Psychiatrists may be uncomfortable responding, since formal genetics training from college or medical school may be poorly remembered and no longer current. Most residents have less than 3 hours of genetics training during the residency itself. Residency training programs frequently do not include faculty with genetics expertise. Some psychiatrists and trainees may erroneously believe that genetics is peripheral to the understanding and treatment of psychiatric illness. A related issue is the limited time for didactics in residency programs and the need for prioritization of subspecialty topics.

The Accreditation Council for Graduate Medical Education (ACGME) indicates that “biological, genetic, psychological, sociocultural, economic, ethnic, gender, religious/spiritual, sexual orientation, and family factors that significantly influence physical and psychological development throughout the life cycle” should be part of the residency training experience. The relative emphasis for these factors differs substantially depending on the needs and resources of the individual institution. The American Board of Psychiatry and Neurology (ABPN) includes genetics in its content specifications; however, in practice, the examinations may not reflect current knowledge and progress in psychiatric genetics. We would encourage both the ACGME and the ABPN to increase emphasis on neuroscience and genetics in their guidance to the field. Since these institutions are critical to the future development of psychiatric training and trainees, we would encourage academic psychiatrists to become involved in these organizations and to encourage constructive change.

The need for knowledge of genetics in psychiatric practice is likely to increase over time. The work done by the Psychiatric Genomics Consortium and other groups has given rise to many different gene associations with psychiatric disorders and associated brain and behavioral phenotypes. Sequencing consortia are now established for many disorders as well. New analytic methods, such as the polygenic risk score and pathway analysis, are increasingly applied in research and may eventually become useful clinically. Pharmacogenomic tests provide the basis for precision medicine in psychiatry and, with careful development through clinical trials, should improve patient care.

Major developments in psychiatric genetics affecting clinical practice may be expected within the next 20 years, the period during which today’s residents will be professionally
active (Table 2). There has been an acceleration of genetic findings relevant to psychiatric illness over the past 10 years, and previous timelines no longer apply. Changes in clinical practice based on genetic findings may be expected to occur from one year to the next. Patients will increasingly expect understanding of new advances in psychiatric genetics and appropriate application by their clinicians. An up-to-date psychiatric genetics curriculum will be required to enable psychiatrists in training to respond to the challenges posed by current and emerging findings in genomics.

In 2015, the International Society of Psychiatric Genetics (ISPG) established a Residency Education Committee. The committee members had general expertise in psychiatric genetics, as well as specific expertise in related fields. The manuscript for this article was developed during 2015–2017 based on review of the literature and a series of discussions among the 13 committee members in person, on quarterly conference calls, and in periodic e-mail exchanges. We were also attentive to the findings of ongoing consortia and consulted regularly with the members of the Society and the ISPG Board of Directors. Notably, the committee has coordinated efforts with the Inter-Society Coordinating Committee for Practitioner Education in Genomics and the National Neuroscience Curriculum Initiative (NNCI), a National Institute of Mental Health-funded program that interacts with the American Association of Directors of Residency Training in Psychiatry. This effort has resulted in a set of resources that are specifically intended to enhance genetics training (publicly available on the NNCI website: www.nncionline.org; Supplementary Table 1). Other online resources are available through the National Human Genome Research Institute–maintained website https://genomicseducation.net.

This article describes the rationale, methods, goals, and recommendations for the incorporation of genetics into psychiatric training. Points that are important for current clinical practice are underlined.

Every physician should have a basic grounding in the process by which genetic information is transmitted between generations, the cell cycle in which germ cells are created and recombine, and the relationship between genetic distance on a chromosome and statistical association due to linkage. What has become more critical in recent years is the application of these principles in methods such as genome-wide association studies (GWAS) and sequencing studies. New knowledge of multiple types of RNA and the role of transcription factors is also important for the physician who wishes to keep up with the genetic literature.

FAMILY STUDIES AND HERITABILITY

The evidence for heritability of the major psychiatric disorders comes from the collection of family, twin, and adoption studies, extending throughout the 20th century. This evidence is substantial for schizophrenia, bipolar disorder, major depression, alcoholism, antisocial personality disorder, and autism spectrum disorders, among other conditions. These data are summarized in many standard psychiatric texts (eg, The Medical Basis of Psychiatry). Heritability is classically calculated as the comparison of monozygotic to dizygotic twin concordance rates, although it can be estimated from comparing other family relationships.
as well. Also important is the concept of relative risk (quantified by lambda), that is, the increased vulnerability of some individuals with a specific risk factor for a disorder compared with the general population. The lambda for the relationship between risk in first-degree relatives of a proband and individuals in the general population for schizophrenia is about 10 and for bipolar I disorder, 8–10.

Empirical information regarding lifetime risk for illness in relatives (morbid risk) gives a basis for estimates of likelihood of illness. This information may be useful to provide when questions arise about risk to an individual or to his/her family members. For most, complex diseases, including major psychiatric disorders, empirical risk figures still form the best, basis for deriving risk estimates for families.

COMMON GENETIC VARIANTS

Common gene variants (those with a prevalence of 1% or greater in the general population) play a large role in psychiatric disorders. Common variants are likely to have quite small effects (relative risk of ~1.1, or an increase in risk of 10% for carriers), whereas rare variants may have larger effects. The effects of common variants may be combined, and it is likely that the major psychiatric disorders result from the combination of variants in hundreds or even thousands of genes.

The polygenicity of psychiatric disorders has certain implications. One is that the variants that influence illness may be expected to be widely distributed in the general population. It is only when the number and effect size of these variants exceed a threshold that a subject will be affected. Another is that the genetic profile of any affected person may be expected to be different from the genetic profile of most other affected individuals. That is, genetic heterogeneity will be very substantial.

Common variant effects may be detected using a GWAS, which tests such effects at markers spaced across the entire genome. Current platforms for GWAS include thousands to millions of individual single-nucleotide polymorphism markers. Each marker is tested for variant frequency differences between cases and controls. Such analyses must be corrected for multiple testing. The currently accepted significance threshold for GWAS is $5 \times 10^{-8}$, and this threshold is generally reached only by using very large sample sizes. A recent schizophrenia GWAS included more than 30,000 cases and resulted in the identification of more than 100 independent genetic loci, which are now being analyzed for clues to pathophysiology.

One may also use GWAS data to improve our understanding of psychiatric disorders in additional ways. Common variant heritability of disorders may be understood quantitatively by genome-wide complex trait analysis. This method has demonstrated substantial common variant heritability for multiple disorders, along with surprising demonstrations of coheritability (eg, a 70% overlap in common genetic vulnerability markers between bipolar disorder and schizophrenia). Other methods now becoming useful in research, and with the potential for clinical utility, include polygenic risk scores, which combine the effects of multiple loci in a single estimate of risk, and pathway analyses, which combine...
effects of multiple loci to understand pathophysiology. Recent data suggest emerging clinical utility for polygenic risk scores.37,38

RARE GENETIC VARIANTS

Rare variants are, by definition, present in < 1% of the population. While the vast majority of rare variants will have small effect, some rare variants have large effects on vulnerability. Some of the most prominent findings involve copy number variants (CNVs), small deletions or duplications of genetic material detectable with molecular techniques. Some, such as the 22q11 deletion, are associated with major psychiatric disorder.39 Chromosomal microarray (CMA) analyses can detect many of these CNVs. The CMA technique (along with fragile X testing) is now widely recommended as a first-line evaluation in the assessment and treatment of autism spectrum disorders.40–44

Rare single-nucleotide variants (SNVs) have also been associated with autism, schizophrenia, and bipolar disorder. Unlike CNVs, SNVs require sequencing to be detected. Sequencing can be targeted to a specific gene, to all the coding portions of the genome (whole exome), or to the entire coding and non-coding parts of the genome (whole genome). These techniques have now become an important diagnostic tool in the evaluation of neurodevelopmental disorders, and they may eventually take the place of microarrays. Both CNVs and SNVs may be inherited from a parent or they may occur de novo (ie, not present in either parent).

Rare variants appear to be implicated in 10%–30% of cases of autism spectrum disorder and up to 3%–5% of cases of bipolar illness and schizophrenia.39 When present, they may be associated with specific medical syndromes.13 If present in the parents, they also may be associated with an increased risk for illness in siblings. Psychiatrists should be aware of the substantial risk that some rare variants confer, when and how to test for them, and the implications of these variants on clinical management of psychiatric conditions.

EPIGENETICS/GENE EXPRESSION

Although the constitutional genome sequence tends to be quite stable, gene expression may change with age, gender, diet, season, time of day, drug and medication use, and exposure to a wide variety of environmental stimuli. Epigenetic events include methylation of genes, modifications of the histone proteins that interact with genes, and other chemical changes influencing gene expression; these effects may persist throughout life and in some cases may even be passed on to the next generation.45 It is possible to measure gene expression in many peripheral tissues including blood and saliva. Blood gene expression appears to parallel brain gene expression for some genes,46 but there are many differences as well.47 We can also observe gene expression changes in cultured cells obtained from the tissue of patients with psychiatric disorders (skin or blood cells). Such cells may offer the opportunity for in vitro models of psychiatric disorders.48

Psychiatrists should be aware of the difference between genetic variation and epigenetic changes, understand the relationship of such changes to gene expression, and be able to evaluate potential biomarker studies employing gene expression. An understanding of
epigenetics can be a very helpful tool in counseling patients about the interaction of genetics and environment in the risk of developing a psychiatric disorder.

**PHARMACOGENETICS/PHARMACOGENOMICS**

Both therapeutic response and adverse side effects of pharmacologic treatments are modulated by genetic factors. The US Food and Drug Administration (FDA) recommends that, patients of Asian descent, be screened for specific human leukocyte antigen variants that put them at elevated risk of developing Stevens-Johnson syndrome when taking carbamazepine. Genetic screening for those at high risk for clozapine-induced agranulocytosis may soon be possible.

The cytochrome P450 (CYP) enzyme system influences metabolism of psychotropic medications including antidepressants and antipsychotics. Several companies now market tests that utilize multiple genetic markers reflecting the status of these metabolic enzymes. Academic laboratories and genetic testing companies have designed proprietary algorithms to predict the combined effect of these variants on drug response and side effects. The efficacy of these pharmacogenomic profiles requires further investigation in controlled studies. However, several hundred thousand tests have already been performed commercially, and the costs may be covered by third-party payers. Two specific enzymes have figured in FDA warnings. Patients who are slow metabolizers based on CYP2C19 should not receive doses of citalopram greater than 20 mg daily. There is a similar warning for doses of vortioxetine greater than 10 mg for slow metabolizers based on CYP2D6.

The quality and utility of pharmacogenomic tests should increase over time. Psychiatrists in training will need to know how to consider whether these products are a useful guide to the management of their patients. They will need to respond to patients who may request such genetic testing or bring results of pharmacogenetic tests to their appointments. The NNCI recently released an educational module that highlights a commentary on this topic.

**ETHICAL AND SOCIAL ISSUES**

During the early 20th century, observations of the familial nature of behavioral disorders led some scientists and social theorists to develop the now discredited eugenics movement. Eugenics was a misguided attempt to implement social control over human reproduction. People with a variety of psychiatric and developmental conditions were encouraged to undergo voluntary sterilization in the United States and Europe. Under the Nazis in the 1930s and 1940s, eugenics was used to justify programs of euthanasia in psychiatric hospitals.

There are still many misconceptions about genetic factors in medical disorders. Patients may be concerned that “If it’s genetic, my children will have it” or “If it’s genetic, it can’t be treated.” There may be reasonable concern about discrimination based on genetic information.

Social use of individual genetic information is fraught with ethical and political problems. African-Americans have been particularly sensitized to issues of genetic stigma since
restrictive regulations have been applied to (mostly African-American) carriers of sickle cell trait (HbS). More generally, screening for the XYY karyotype was carried out among newborns in Boston (1968–1975), following data indicating an association between XYY and antisocial personality disorder. The program was stopped because of justifiable concern regarding stigmatization and inadequate consent procedures.

Misconceptions about such use of genetic data need to be addressed. Our trainees require the knowledge necessary to approach such issues with sensitivity to the ethical issues involved.

**PRINCIPLES OF RISK COMMUNICATION**

Addressing families’ concerns about risks for psychiatric disorders still currently relies heavily on empirical risk figures derived from family studies; efforts should be made to adapt the data to the unique family situation. Psychiatrists should be able to talk with patients and families about the hereditary nature of many psychiatric disorders and how this varies in the setting of a given genetic variant. They should be comfortable with explaining probabilistic concepts of inheritance. In the area of autism and intellectual disability, they will increasingly be expected to refer patients for genetic testing and to help them understand the results of such tests.

There are psychological issues inherent in the reception and interpretation of genetic data. Patients may find knowledge regarding a genetic condition in their family either liberating or burdensome. Self-concept may be affected. Decisions about childbearing are intensely personal and emotional. Guilt, shame, fear, and stigma are often attached to people’s explanations for cause of illness. Although addressing emotions such as these lies squarely within the domain of expertise of psychiatrists, genetic counselors are also uniquely equipped to address these challenges, and thus collaboration is important. Formal exposure to genetic counselors and to their work with patients and families dealing with neuropsychiatric syndromes would be an excellent training experience for psychiatric residents.

Key points from the text for psychiatric clinicians are summarized in Table 2. A glossary of commonly used genetic terms is available from the National Human Genome Research Institute (https://www.genome.gov/glossary).

**CONCLUSIONS**

Every psychiatrist should know the basic principles of genetics, the role of genes in psychiatric disorders and their treatment, the ways in which environment affects gene expression, ethical issues in the use of genetic information, and how to talk to patients and families about genetics. These should no longer be thought of as optional or special-interest areas in psychiatric training. They are essential to current psychiatric patient care. We face multiple challenges in meeting these essential training goals. There is a paucity of faculty with the necessary expertise in many departments of psychiatry; there are severe time limitations for didactic sessions in residency programs with many competing needs; and, historically, there has been a tendency for some psychiatrists to regard genetics and neurobiology as secondary to other aspects of clinical practice. We would encourage
residency programs to emphasize experiential problem-solving exercises (such as those available from the NNCI) in addition to a limited number of overview classroom lectures. Informal seminars and journal clubs can also be used to tackle genetic topics in a setting that allows for more questions and discussion than the lecture format. Residents should be encouraged to attend meetings that include sophisticated presentations of genetic data (such as Biological Psychiatry, American College of Neuropsychopharmacology, and the World Congress of Psychiatric Genetics). It should be expected that departments of psychiatry will increasingly appreciate the need for faculty with specialized expertise in this area as new findings emerge and the intersection of genetics with clinical practice increases. Genetics education among psychiatric residents should become an essential part of the emerging agenda for the development of a new cadre of psychiatric professionals for the 21st century.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments:

Helpful and critical input was provided by interactions with J. Raymond De Paulo, Jr, MD, and the ISPG Genetic Testing and Global Diversity Committees.

**Funding/support:** Support was provided by Parthenon Management Company, the National Human Genome Institute’s Inter-Society Coordinating Committee for Practitioner Education in Genomics (www.genome.gov/27554614), and the National Neuroscience Curriculum Initiative (R25 MH10107602S1 and R25 MH086466 07S1, to Dr Ross and colleagues).

**Role of the sponsor:** The content of the manuscript for this article was solely determined by the International Society of Psychiatric Genetics through its Residency Education Committee. No company contributed to the content of this manuscript or to the interpretation of data contained herein.

REFERENCES


Clinical Points

- Psychiatric genetics knowledge and its application are not well covered in current residency programs.
- Residents should consider genetic testing as a standard part of the diagnostic workup for patients with autism spectrum disorders or intellectual disability.
- Pharmacogenomic testing is not generally indicated but may be helpful in certain situations (eg, carbamazepine, citalopram).
- Direct-to-consumer testing results may be misleading.
Table 1.
Representative Genetic Contribution to Different Psychiatric Disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Common Variants</th>
<th>Rare Variants</th>
<th>Heritability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schizophrenia</td>
<td>Clear (100+)$^3$</td>
<td>CNVs,$^2$ SNVs$^3$</td>
<td>81%$^4$</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>Clear (30+)$^5$</td>
<td>CNVs,$^2$ SNVs$^6$</td>
<td>85%$^4$</td>
</tr>
<tr>
<td>Major depression</td>
<td>Clear (14)$^7$</td>
<td>Unknown</td>
<td>37%$^4$</td>
</tr>
<tr>
<td>Anxiety disorders</td>
<td>In process</td>
<td>Unknown</td>
<td>Panic: 43%$^4$ GAD: 28%$^4$</td>
</tr>
<tr>
<td>OCD</td>
<td>In process</td>
<td>Unknown</td>
<td>40%$^8$</td>
</tr>
<tr>
<td>Substance use disorders</td>
<td>Clear$^9$</td>
<td>Unknown</td>
<td>Cocaine: 72%$^4$ Alcohol: 56%$^4$ Cannabis: 48%$^4$</td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>Clear (20+)$^{10}$</td>
<td>Rare Mendelian$^{10}$</td>
<td>75%$^4$</td>
</tr>
<tr>
<td>Intellectual disability</td>
<td>Clear$^{11}$</td>
<td>CNVs,$^2$ SNVs$^{12}$</td>
<td>50%$^{11}$</td>
</tr>
<tr>
<td>Autism spectrum disorder</td>
<td>Clear$^{13}$</td>
<td>CNVs,$^2$ SNVs$^{13}$</td>
<td>78%$^{14}$</td>
</tr>
<tr>
<td>ADHD</td>
<td>Clear$^{15}$</td>
<td>Unknown</td>
<td>62%$^{16}$</td>
</tr>
<tr>
<td>Eating disorders</td>
<td>Clear$^{17}$</td>
<td>Unknown</td>
<td>Anorexia: 60%$^4$</td>
</tr>
</tbody>
</table>

Abbreviations: ADHD = attention-deficit/hyperactivity disorder, CNV = copy number variant, GAD = generalized anxiety disorder, OCD = obsessive-compulsive disorder, SNV = single-nucleotide variant.
Table 2.
Why Do Today’s Psychiatric Residents Need to Understand Genetics?

<table>
<thead>
<tr>
<th>A. Clinical situations in which genetic knowledge is already required</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Estimating empirical risk for psychiatric illness from family structure information and epidemiologic studies</td>
</tr>
<tr>
<td>2. Ordering and interpreting genetic tests for autism spectrum disorders and intellectual disability</td>
</tr>
<tr>
<td>3. Evaluating the need for pharmacogenomic testing and interpreting the results</td>
</tr>
<tr>
<td>4. Addressing the results of direct-to-consumer genetic tests in clinical practice</td>
</tr>
<tr>
<td>5. Knowing when to consult genetic counselors and medical geneticists</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. Areas in which new applications of genetics may be expected in the next 1–2 decades</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Estimating empirical risk in the presence of specific copy number variants and single nucleotide variants</td>
</tr>
<tr>
<td>2. Ordering and interpreting genetic tests for rare variants in schizophrenia and bipolar disorder</td>
</tr>
<tr>
<td>3. Applying genetic risk scoring in a clinical framework</td>
</tr>
<tr>
<td>4. Developing personal genetic profiles for patients and interpretation for treatment decisions and personal prognosis</td>
</tr>
</tbody>
</table>